The safety profile of vedolizumab in ulcerative colitis and Crohn's disease: 4 years of global post-marketing data
<p><strong>Background and Aims</strong> Vedolizumab is a gut-selective antibody to α<sub>4</sub>β<sub>7</sub> integrin approved to treat moderate-to-severe ulcerative colitis and Crohn’s disease in adults. Clinical trial data on patients meeting protocol-spe...
| Main Authors: | , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Oxford University Press
2019
|